ArticleJournal of translational medicine2024

IL-18, a therapeutic target for immunotherapy boosting, promotes temozolomide chemoresistance via the PI3K/AKT pathway in glioma.

Huangyi Ji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.